{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:49:45Z","timestamp":1784893785207,"version":"3.55.0"},"reference-count":55,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM17074"],"award-info":[{"award-number":["LSHM17074"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,9,21]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease that affects up to 30% of patients with psoriasis. Current challenges in clinical care and research include personalised treatment, understanding the divergence of therapy response and unravelling the multifactorial pathophysiology of this complex disease. Moreover, there is an urgent clinical need to predict, assess and understand the cellular and molecular pathways underlying the response to disease-modifying antirheumatic drugs (DMARDs). The TOFA-PREDICT clinical trial addresses this need. Our primary objective is to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this investigator-initiated, phase III, multicentre, open-label, four-arm randomised controlled trial, we plan to integrate clinical, molecular and imaging parameters of 160 patients with PsA. DMARD-na\u00efve patients are randomised to methotrexate or tofacitinib. Additionally, patients who are non-responsive to conventional synthetic (cs)DMARDs continue their current csDMARD and are randomised to etanercept or tofacitinib. This results in four arms each with 40 patients. Patients are followed for 1\u2009year. Treatment response is defined as minimal disease activity at week 16. Clinical data, biosamples and images are collected at baseline, 4 weeks and 16 weeks; at treatment failure (treatment switch) and 52 weeks. For the first 80 patients, we will use a systems medicine approach to assess multiomics biomarkers and develop a prediction model for treatment response. Subsequently, data from the second 80 patients will be used for validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the Medical Research Ethics Committee in Utrecht, Netherlands, is registered in the European Clinical Trials Database and is carried out in accordance with the Declaration of Helsinki. The study\u2019s progress is monitored by Julius Clinical, a science-driven contract research organisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EudraCT: 2017-003900-28.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064338","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:15:02Z","timestamp":1665404102000},"page":"e064338","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)"],"prefix":"10.1136","volume":"12","author":[{"given":"Nienke J","family":"Kleinrensink","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Radiology, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-0104","authenticated-orcid":false,"given":"Frank T","family":"Perton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-7833","authenticated-orcid":false,"given":"Juli\u00ebtte N","family":"Pouw","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-4814","authenticated-orcid":false,"given":"Nanette L A","family":"Vincken","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita A Y","family":"Hartgring","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1929-6350","authenticated-orcid":false,"given":"Myl\u00e8ne P","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Arbabi","sequence":"additional","affiliation":[{"name":"Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TOFA-PREDICT author group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-8555","authenticated-orcid":false,"given":"Wouter","family":"Foppen","sequence":"additional","affiliation":[{"name":"Radiology, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim A","family":"de Jong","sequence":"additional","affiliation":[{"name":"Radiology, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Tekstra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmerik F A","family":"Leijten","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris P J G","family":"Lafeber","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes W","family":"Heijstek","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2025121402530090000_12.10.e064338.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025121402530090000_12.10.e064338.2","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"key":"2025121402530090000_12.10.e064338.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"2025121402530090000_12.10.e064338.4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.berh.2019.03.001","article-title":"Opportunities and challenges in the treatment of psoriatic arthritis","volume":"32","author":"FitzGerald","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025121402530090000_12.10.e064338.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes324"},{"key":"2025121402530090000_12.10.e064338.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"2025121402530090000_12.10.e064338.7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamadermatol.2015.1986","article-title":"Association of psoriatic disease with uveitis","volume":"151","author":"Egeberg","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025121402530090000_12.10.e064338.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.35.4.354"},{"key":"2025121402530090000_12.10.e064338.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140021"},{"key":"2025121402530090000_12.10.e064338.10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10067-018-4332-7","article-title":"Role of comorbidities in spondyloarthritis including psoriatic arthritis","volume":"38","author":"Scriffignano","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025121402530090000_12.10.e064338.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"2025121402530090000_12.10.e064338.12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2016.1139453","article-title":"Psoriatic arthritis: complexities, comorbidities and implications for the clinic","volume":"12","author":"Haroon","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121402530090000_12.10.e064338.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150938"},{"key":"2025121402530090000_12.10.e064338.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"2025121402530090000_12.10.e064338.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202608"},{"key":"2025121402530090000_12.10.e064338.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201972"},{"key":"2025121402530090000_12.10.e064338.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190083"},{"key":"2025121402530090000_12.10.e064338.18","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0785-6","article-title":"Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics","volume":"20","author":"Haberman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2025121402530090000_12.10.e064338.19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.autrev.2018.11.007","article-title":"Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease","volume":"18","author":"Chimenti","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025121402530090000_12.10.e064338.20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.berh.2018.09.006","article-title":"Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis","volume":"32","author":"Solmaz","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025121402530090000_12.10.e064338.21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology"},{"key":"2025121402530090000_12.10.e064338.22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.41516","article-title":"Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis","volume":"73","author":"Tao","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025121402530090000_12.10.e064338.23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/1744666X.2019.1580144","article-title":"Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development","volume":"15","author":"Leijten","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121402530090000_12.10.e064338.24","doi-asserted-by":"crossref","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025121402530090000_12.10.e064338.25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (grappa): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025121402530090000_12.10.e064338.26","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025121402530090000_12.10.e064338.27","article-title":"Methotrexate for psoriatic arthritis","volume":"1","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121402530090000_12.10.e064338.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2025121402530090000_12.10.e064338.29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S56073","article-title":"Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders","volume":"9","author":"D'Angelo","year":"2017","journal-title":"Open Access Rheumatol"},{"key":"2025121402530090000_12.10.e064338.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2025121402530090000_12.10.e064338.31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2025121402530090000_12.10.e064338.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2025121402530090000_12.10.e064338.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181093"},{"key":"2025121402530090000_12.10.e064338.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.04.005"},{"key":"2025121402530090000_12.10.e064338.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025121402530090000_12.10.e064338.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.187"},{"key":"2025121402530090000_12.10.e064338.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"2025121402530090000_12.10.e064338.38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449"},{"key":"2025121402530090000_12.10.e064338.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025121402530090000_12.10.e064338.40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the future 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025121402530090000_12.10.e064338.41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.24242","article-title":"Measuring outcomes in psoriatic arthritis","volume":"72 Suppl 10","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025121402530090000_12.10.e064338.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048975"},{"key":"2025121402530090000_12.10.e064338.43","first-page":"S64","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander\/Newcastle Enthesitis index (Mei), Leeds Enthesitis index (LEI), spondyloarthritis research Consortium of Canada (SPARCC), Maastricht ankylosing spondylitis Enthesis score (MASES), Leeds Dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness Therapy-Fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025121402530090000_12.10.e064338.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210747"},{"key":"2025121402530090000_12.10.e064338.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2025121402530090000_12.10.e064338.46","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2025121402530090000_12.10.e064338.47","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"2025121402530090000_12.10.e064338.48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1346-8138.1999.tb03458.x","article-title":"The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial","volume":"26","author":"Fleischer","year":"1999","journal-title":"J Dermatol"},{"key":"2025121402530090000_12.10.e064338.49","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2025121402530090000_12.10.e064338.50","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1564696"},{"key":"2025121402530090000_12.10.e064338.51","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090352"},{"key":"2025121402530090000_12.10.e064338.52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","article-title":"EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies","volume":"44","author":"Aide","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025121402530090000_12.10.e064338.53","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64 Suppl 2","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025121402530090000_12.10.e064338.54","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2191-5"},{"key":"2025121402530090000_12.10.e064338.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000527"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T10:53:11Z","timestamp":1765709591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,10]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2022-064338"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064338","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}